Perimeter Medical Imaging AI (PYNKF) announced the submission of a Premarket Approval application to the U.S. Food and Drug Administration for the Company’s next-generation Perimeter B-Series OCT system, which combines proprietary artificial intelligence technology with optical coherence tomography, for use during breast-conserving surgeries in the United States. In November 2024, Perimeter reported topline results from the pivotal study designed to support the Company’s FDA PMA for B-Series OCT with ImgAssist AI 2.0 for use during breast-conserving surgeries in the United States. The pivotal trial met its primary endpoint, achieving a statistically significant reduction in patients with residual cancer during surgery. These results demonstrated super-superiority of the Perimeter B-Series OCT with ImgAssist AI 2.0 system’s ability to aid surgeons in achieving clear surgical margins during surgery, potentially lowering the need for reoperation.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYNKF:
- Perimeter Medical Imaging AI Submits FDA Application for Advanced Imaging System
- Perimeter Medical’s Pivotal Trial Results to be Presented at ASBrS 2025
- OTC Markets welcomes Perimeter Medical Imaging AI to OTCQX
- Perimeter Medical Imaging AI to Trade on OTCQX, Eyes U.S. Expansion
- Perimeter Medical Imaging AI to Host Investor Webinar
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue